Because no information is available on the use of felbamate during breastfeeding, and because it can cause potentially fatal hematologic and hepatic toxicities, authors of authoritative reviews recommend that breastfeeding not be undertaken during maternal felbamate therapy until more safety data are available.[1,2]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Bar-Oz B, Nulman I, Koren G, et al. Anticonvulsants and breastfeeding. A critical review. Paediatr Drugs. 2000;2:113–26. [PubMed: 10937463]
2.
Hägg S, Spigset O. Anticonvulsant use during lactation. Drug Saf. 2000;22:425–40. [PubMed: 10877037]
Substance Identification
Substance Name
Felbamate
CAS Registry Number
25451-15-4
Drug Class
Breast Feeding
Lactation
Anticonvulsants
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
